The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact

Affiliations

• ¹ Center for Vaccine Biology and Immunology; Department of Microbiology and Immunology, University of Rochester, Rochester, NY.
• ² Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY.
• ³ Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY.
• ⁴ Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA.
• ⁵ AstraZeneca, South San Francisco, CA.
• ⁶ Department of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
• ⁷ Center for Vaccine Biology and Immunology; Department of Microbiology and Immunology, University of Rochester, Rochester, NY, USA; Center for Cell Clearance and the Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA. mre4n@virginia.edu.
• ⁸ Department of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY. charles_chu@urmc.rochester.edu.